Zimbabwe has declined a significant US health deal worth $367m (272 million pounds) over five years over Washington's demand for sensitive biological samples.
The decision was revealed after a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesman has since stated that the United States was requesting health data for scientific study and commercial gain but was unwilling to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more talks to secure a deal suitable to both sides so the country's critical HIV programme can be sustained.
Broader Background
Zimbabwe's decision comes after a comparable case in Kenya, where a court halted a related deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government deals to enhance openness and responsibility.
As per reports, Sixteen African countries have so far signed these new agreements, representing more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data for a long time, without any corresponding promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the end products would be available to our citizens if a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining systems already established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This framework is designed to ensure that when a country contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We welcome ongoing discussions with our American counterparts on how future collaboration might be designed in a way that honours the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but recommended that negotiations must proceed since a large portion of the country's Aids initiatives relied on international support.
"In cases where technical issues exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.
The situation emphasises the continuing debate between receiving vital international aid and safeguarding national sovereignty in an increasingly data-driven world.